Bile Duct Neoplasms Pipeline Analysis Report 2025

Bile duct neoplasms are abnormal growths in the bile ducts. These growths can be benign (bile duct adenomas) or malignant (cholangiocarcinoma). Cholangiocarcinoma is the most prevalent type of cancer that develops from glandular cells that line the bile ducts and is divided into three locations, namely, intrahepatic, perihilar, and distal. Bile duct adenomas and other benign tumors are uncommon and frequently discovered by accident after surgery or autopsy. The bile duct neoplasms pipeline analysis by the publisher focuses on various treatment options for this disease.

Report Coverage

The Bile Duct Neoplasms Pipeline Analysis Report by the publisher gives comprehensive insights into bile duct neoplasms currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Bile Duct Neoplasms therapeutics. The bile duct neoplasms report assessment includes the analysis of over 15 pipeline drugs and 10+ companies. The bile duct neoplasms pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with bile duct neoplasms treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to bile duct neoplasms.

Bile Duct Neoplasms Pipeline Outlook

Cholangiocytes give rise to bile duct neoplasms, which frequently entail chronic inflammation (from cholestasis, infections, or stones). It leads to genetic alterations which promote carcinogenesis, such as KRAS (early) and TP53 (late). Biliary intraepithelial neoplasia (BilIN) and intraductal papillary neoplasm (IPNB) are examples of premalignant lesions that show mucin production and papillary development. Long-term inflammation causes dysplasia, which damages the bile duct epithelium and creates a "vicious cycle" of cell division and DNA damage.

The resectable nature of bile duct neoplasm determines the course of treatment. The main treatment option is surgery, which may include resection of the liver or pancreas as well as excision of the bile duct. Chemotherapy (such as gemcitabine-cisplatin) and immunotherapy (such as pembrolizumab) aid in regulating tumor growth in situations that cannot be cured. Radiation therapy and photodynamic therapy relieve symptoms, whereas targeted therapies target mutations. Stent insertion is one palliative surgery that reduces jaundice and enhances quality of life.

Bile Duct Neoplasms Epidemiology

Rare, bile duct neoplasm varies greatly in geography and demographics. About 8,000 cases of bile duct cancer are detected in the United States each year. Intrahepatic cancer is more common (1.49 per 100,000) than extrahepatic cancer (0.96 per 100,000). Infections with liver flukes are more common in Southeast Asia. Males and older persons are more likely to be impacted, and all groups continue to have low survival rates.

Bile Duct Neoplasms - Pipeline Therapeutic Assessment

This section of the report covers the analysis of bile duct neoplasms drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Monoclonal antibody
• Peptides
• Small molecule
• Gene Therapy

By Route of Administration

• Oral
• Parenteral
• Others

Bile Duct Neoplasms - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total bile duct neoplasms clinical trials.

In the bile duct neoplasms pipeline, most candidates are in Phase II with 47% of the projects, followed by 35% in Phase I and 18% in Phase III demonstrating a broad spectrum of development stages and diverse progress toward potential treatments.

Bile Duct Neoplasms - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the bile duct neoplasms pipeline analysis include monoclonal antibody, peptides, small molecule and gene therapy. The bile duct neoplasms report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Bile Duct Neoplasms.

Bile Duct Neoplasms Clinical Trials - Key Players

The report for the bile duct neoplasms pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in bile duct neoplasms clinical trials:

• Merck Sharp & Dohme LLC
• Endeavor Biomedicines, Inc.
• Carisma Therapeutics Inc.
• Elicio Therapeutics
• OncoC4, Inc.

Bile Duct Neoplasms Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for bile duct neoplasms. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of bile duct neoplasms drug candidates.

Drug: Pembrolizumab

Pembrolizumab, developed by Merck Sharp & Dohme LLC, is in Phase 3 of a clinical trial for treating biliary duct neoplasm. The trial evaluates its safety and efficacy, particularly in combination with chemotherapy, aiming to improve progression-free and overall survival. Pembrolizumab is an anti-PD-1 monoclonal antibody that boosts the immune system's ability to detect and fight cancer cells.

Drug: ENV- 101

Endeavor Biomedicines’ ENV-101 is currently in Phase 2 of a clinical trial to treat bile duct neoplasms. In patients with solid tumors that have progressed, the trial assesses its safety, tolerability, and initial effectiveness. To reduce tumor growth and improve patient outcomes, ENV-101, an inhibitor of the hedgehog pathway, targets and blocks aberrant cell signaling.

Key Questions Answered in the Bile Duct Neoplasms Pipeline Analysis Report

• Which companies/institutions are leading the bile duct neoplasms drug development?
• What is the efficacy and safety profile of bile duct neoplasms pipeline drugs?
• Which company is leading the bile duct neoplasms pipeline development activities?
• What is the current bile duct neoplasms commercial assessment?
• What are the opportunities and challenges present in the bile duct neoplasms pipeline landscape?
• Which company is conducting major trials for bile duct neoplasms drugs?
• Which companies/institutions are involved in bile duct neoplasms collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in bile duct neoplasms?

Reasons To Buy This Report

The Bile Duct Neoplasms Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for bile duct neoplasms. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into bile duct neoplasms collaborations, regulatory environments, and potential growth opportunities.

This product will be delivered within 3-5 business days.